Literature DB >> 2563773

New 4-(heteroanilido)piperidines, structurally related to the pure opioid agonist fentanyl, with agonist and/or antagonist properties.

J R Bagley1, R L Wynn, F G Rudo, B M Doorley, H K Spencer, T Spaulding.   

Abstract

A research program based on certain heterocyclic modifications (12-50) of the fentanyl (1) molecule has generated a novel class of opioids. In the mouse hot-plate test, these compounds were weaker analgesics than 1. Two types of antagonists were observed in morphine-treated rabbits: those (e.g., 28) that reversed both respiratory depression and analgesia and those (e.g. 32) that selectively reversed respiratory depression. Evaluation of in vitro binding affinities to rat brain opioid receptors was inconclusive for a common locus of action for the agonist as well as the antagonist component. Further pharmacological evaluation of 32, N-(2-pyrazinyl)-N-(1-phenethyl-4-piperidinyl)-2-furamide, in the rat showed it to be a potent analgesic (ED50 = 0.07 mg/kg, tail-flick test) with little cardiovascular and respiratory depression when compared to fentanyl.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2563773     DOI: 10.1021/jm00123a028

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Pharmacological profile of a potent, efficacious fentanyl derivative in rhesus monkeys.

Authors:  C P France; G Winger; M R Seggel; K C Rice; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.

Authors:  W Jeal; P Benfield
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 3.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

Authors:  Ruben S Vardanyan; Victor J Hruby
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

4.  Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity.

Authors:  Ravil R Petrov; Ruben S Vardanyan; Yeon S Lee; Shou-wu Ma; Peg Davis; Lucinda J Begay; Josephine Y Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2006-07-07       Impact factor: 2.823

5.  Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.

Authors:  N Zaveri; W E Polgar; C M Olsen; A B Kelson; P Grundt; J W Lewis; L Toll
Journal:  Eur J Pharmacol       Date:  2001-09-28       Impact factor: 4.432

Review 6.  Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.

Authors:  R B Muijsers; A J Wagstaff
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated.

Authors:  Neil B Varshneya; Sherif H Hassanien; Melissa C Holt; David L Stevens; Nathan K Layle; Jonathon R Bassman; Donna M Iula; Patrick M Beardsley
Journal:  Biochem Pharmacol       Date:  2021-10-19       Impact factor: 6.100

8.  Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances.

Authors:  Neil B Varshneya; D Matthew Walentiny; Lea T Moisa; Teneille D Walker; Luli R Akinfiresoye; Patrick M Beardsley
Journal:  Neuropharmacology       Date:  2019-03-20       Impact factor: 5.250

9.  Hyperpolarization of Pyridyl Fentalogues by Signal Amplification By Reversible Exchange (SABRE).

Authors:  Thomas B R Robertson; Lysbeth H Antonides; Nicolas Gilbert; Sophie L Benjamin; Stuart K Langley; Lindsey J Munro; Oliver B Sutcliffe; Ryan E Mewis
Journal:  ChemistryOpen       Date:  2019-11-08       Impact factor: 2.911

Review 10.  Fentanyl Structure as a Scaffold for Opioid/Non-Opioid Multitarget Analgesics.

Authors:  Piotr F J Lipiński; Joanna Matalińska
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.